Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits

Factor XII inhibition reduces thrombus formation in a primate thrombosis model

(2014) A. Matafonov et al.   BLOOD

Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits

(2014) Jonathan W. Yau et al.   BLOOD

A specific antidote for dabigatran: functional and structural characterization

(2013) F. Schiele et al.   BLOOD

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

(2013) Sam Schulman et al.   CIRCULATION

Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer

(2013) R. S. Woodruff et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran and Mechanical Heart Valves — Not as Easy as We Hoped

(2013) Elaine M. Hylek   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

(2013) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

A nanobody-based method for tracking factor XII activation in plasma

(2013) Steven de Maat et al.   THROMBOSIS AND HAEMOSTASIS

A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients

(2013) Pascal Vranckx et al.   EuroIntervention

Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo

(2012) Jonathan W. Yau et al.   Acta Biomaterialia

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

(2012) Joachim Stangier et al.   BLOOD COAGULATION & FIBRINOLYSIS

Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition

(2012) Sara S. Cheng et al.   INTENSIVE CARE MEDICINE

Epidemiology and prevention of catheter-related thrombosis in patients with cancer

(2012) A. Y. Y. LEE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo

(2011) J. W. Yau et al.   BLOOD

Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding

(2011) A. S. Revenko et al.   BLOOD

Dabigatran Etexilate

(2011) Graeme J. Hankey et al.   CIRCULATION

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

(2011) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial

(2010) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions

(2009) C. A. Kretz et al.   THROMBOSIS AND HAEMOSTASIS